Phaseline

Companies › BioAge Labs

BioAge Labs: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Ophthalmology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BGE-102
Decreases inflammation
–Phase 2Obesity and Cardiovascular Risk; Diabetic Macular Edema (DME)Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07656727BGE-102Phase 2Obesity and Cardiovascular RiskCardiovascularNov 2026
NCT07812090BGE-102Phase 2Diabetic Macular Edema (DME)OphthalmologyNov 2027

From the company's SEC filings

Cash and short-term investments of $284m on 2026-09-30; operating cash outflow about $100m a year; runway about 34 months at that burn, to Aug 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tectonic Therapeutic Cytokinetics Kiora Pharmaceuticals Vantage Biosciences Nyrada

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.